典型文献
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
文献摘要：
Recently, in cooperation with the Netherlands Cancer Institute, we demonstrated that epidermal growth factor receptor (EGFR) activation limited the response of liver cancer to lenvatinib. The original article was published in Nature as a cover story, which resulted in considerable attention from major scientific jour-nals.
文献关键词：
中图分类号：
作者姓名：
Yuchen Guo;Yangyang Zhou;Wenxin Qin
作者机构：
State Key Laboratory of Oncogenes and Related Genes,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200032,China
文献出处：
引用格式：
[1]Yuchen Guo;Yangyang Zhou;Wenxin Qin-.A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer)[J].癌症生物学与医学（英文版）,2022(02):136-139
A类：
lenvatinib
B类：
CRISPR,Cas9,screen,shows,combination,efficacy,plus,epidermal,growth,receptor,inhibitors,treatment,liver,cancer,Recently,cooperation,Netherlands,Cancer,Institute,we,demonstrated,that,EGFR,activation,limited,response,original,article,was,published,Nature,cover,story,which,resulted,considerable,attention,from,major,scientific,jour,nals
AB值：
0.719386
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
